GE HealthCare Acquires Icometrix to Strengthen Brain MRI Analysis Capabilities for Alzheimer's Drug Monitoring
Key Insights
GE HealthCare has acquired brain analysis company Icometrix (search) for an undisclosed sum to expand its Alzheimer's disease diagnostic capabilities.
The acquisition centers on Icometrix (search)'s FDA-cleared icobrain aria (search) software, which detects and quantifies ARIA side effects from new Alzheimer's drugs like Leqembi and Kisunla.
Clinical validation showed the AI-powered software significantly improved radiologists' detection and diagnosis of brain swelling and bleeding complications across 199 test cases.
GE HealthCare has struck a deal to acquire brain analysis company Icometrix (search) for an undisclosed sum, positioning the medical technology giant to capitalize on the growing need for specialized imaging software to monitor side effects from newly approved Alzheimer's disease treatments.
The acquisition announced Wednesday focuses primarily on Icometrix (search)'s FDA-cleared icobrain aria (search) module, which addresses a critical safety monitoring requirement for recently launched Alzheimer's drugs including Eisai and Biogen's Leqembi and Eli Lilly's Kisunla.
Addressing Critical Safety Monitoring Needs
The approvals of these amyloid-targeting antibodies advanced Alzheimer's treatment for the first time in decades, but introduced new monitoring challenges. The drugs can cause amyloid-related imaging abnormalities (ARIA (search)), forms of swelling or bleeding in the brain that are visible on MRI scans and require careful detection and quantification.
Icometrix (search) developed its icobrain aria (search) software specifically to support detection and quantification of these side effects. The Food and Drug Administration cleared the module in November, enabling it to provide information on the presence, location, size, severity and changes of two types of ARIA adverse events: ARIA-E and ARIA-H, defined by the accumulation of fluid and bleeding, respectively.
Clinical Validation Demonstrates Improved Detection
The software's effectiveness was validated in a clinical study where 16 radiologists assessed 199 cases. The study demonstrated that icobrain aria (search)-assisted reading performance was superior to unassisted reading for all ARIA detection co-primary endpoints, with significant improvements in both ARIA detection and diagnosis accuracy.
GE HealthCare plans to expand access to the Alzheimer's module across all vendor MRI systems through commercial distribution and clinical integration, potentially broadening the software's reach beyond GE's own imaging equipment.
Strategic Expansion in Alzheimer's Diagnostics
The Icometrix (search) acquisition represents the latest move in GE HealthCare's broader expansion into Alzheimer's diagnostics. "Momentum began two years ago with the FDA approval of the first amyloid-targeting therapies," GE HealthCare CEO Peter Arduini said on an earnings call in July. "Since then, we acquired MIM Software (search) and have integrated differentiating amyloid assessment and therapy monitoring tools into our devices."
Broader Brain Imaging Portfolio
Beyond Alzheimer's applications, Icometrix (search) has developed modules to help radiologists and neurologists compare and quantify brain MRI scans for multiple neurological disorders including multiple sclerosis, dementia, epilepsy, stroke and traumatic brain injury. The company received initial 510(k) clearance for its brain imaging software in 2016 and subsequently obtained clearances for specialized modules.
The company previously revealed integration of its AI-powered quantitative reporting software with Philips' MRI scanners and deployment on Philips' healthcare informatics platform, demonstrating established partnerships across the medical imaging ecosystem that GE HealthCare now inherits through the acquisition.